首页 中华结核和呼吸杂志 2020年43卷1期 浅谈结核病合并慢性肝病的抗结核药物治疗
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 专题笔谈 •
ENGLISH ABSTRACT
浅谈结核病合并慢性肝病的抗结核药物治疗
杨松 
严晓峰 
唐神结
作者及单位信息
·
DOI： 10.3760/cma.j.issn.1001-0939.2020.01.002
Brief discussion on anti-tuberculosis medication for tuberculosis complicated with chronic liver disease
Yang Song
Yan Xiaofeng
Tang Shenjie
Authors Info & Affiliations
Yang Song
Yan Xiaofeng
Tang Shenjie
·
DOI： 10.3760/cma.j.issn.1001-0939.2020.01.002
1146
386
0
0
5
5
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
结核病合并慢性肝病患者抗结核药物治疗方案的制定常困扰着感染和结核科医生，目前国内外缺乏共识或指南可供参考。为最大程度避免肝毒性发生和保证疗程完成并获得治愈，本文查阅文献并结合笔者的临床经验浅谈二者的治疗现状。
引用本文
杨松,严晓峰,唐神结. 浅谈结核病合并慢性肝病的抗结核药物治疗[J]. 中华结核和呼吸杂志,2020,43(1)：3-8.
DOI:10.3760/cma.j.issn.1001-0939.2020.01.002PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
参考文献
[1]
Thulstrup AM , Mmle I , Svendsen N ,et al. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study[J]. Epidemiol Infect, 2000,124(2):221-225. DOI:
10.1017/s0950268899003593
.
[2]
Baijal R , Praveenkumar HR , Amarapurkar DN ,et al. Prevalence of tuberculosis in patients with cirrhosis of liver in western India[J]. Trop Doct, 2010,40(3):163-164. DOI:
10.1258/td.2010.090463
.
[3]
Nooredinvand HA , Connell DW , Asgheddi M ,et al. Viral hepatitis prevalence in patients with active and latent tuberculosis[J]. World J Gastroenterol, 2015,21(29):8920-8926. DOI:
10.3748/wjg.v21.i29.8920
.
[4]
Wu PH , Lin YT , Hsieh KP ,et al. Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease: a nationwaide population-based study[J]. Medicine, 2015,94(33):1-7. DOI:
10.1097/MD.0000000000001328
.
[5]
Peng YC , Lin CL , Hsu WY ,et al. Risk of liver cirrhosis in patients with tuberculosis: a nationwide cohort study[J]. Eur J Clin Invest, 2015,45(7):663-669. DOI:
10.1111/eci.12453
.
[6]
Sharma P , Tyagi P , Singla V ,et al. Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis[J]. J Clin Exp Hepatol, 2015,5(1):8-13. DOI:
10.1016/j.jceh.2015.01.003
.
[7]
Hung TH , Lay CJ , Tseng CW ,et al.
The effect of tuberculosis
on the mortality of cirrhotic patients: a population-based 3-year follow-up study
[J]. Medicine, 2014,93(28):1-5. DOI:
10.1097/MD.0000000000000295
.
[8]
Çalışkan B , Somer A , Hatipoğlu N ,et al. Tuberculous liver abscess in an immunocompetent child with pulmonary tuberculosis as a cause of fever of unknown origin[J]. Turk J Pediatr, 2015,57(1):85-89. PMID: 26613227.
[9]
Vaz AM , Peixe B , Ornelas R ,et al. Peritoneal Tuberculosis as a cause of ascites in a patient with cirrhosis[J]. BMJ Case Rep, 2017,2017.
10.1136/bcr-2017-220500
. DOI:.
[10]
Liao JR , Zhang D , Wu XL . Pulmonary tuberculosis combined with hepatic tuberculosis: a case report and literature review[J]. Clin Respir J, 2015,9(4):501-505. DOI:
10.1111/crj.12167
.
[11]
Riberiro S , Trabulo D , Cardoso C ,et al. Disseminated tuberculosis in an immunocompetent patient: the answer is in the liver[J]. GE Port J Gastroenterol, 2016,23(4):208-213. DOI:
10.1016/j.jpge.2015.10.002
.
[12]
Ribeiro R , Patrício C , Silva FP ,et al. Erythema induratum of Bazin and Ponçet′s arthropathy as epiphenomena of hepatic tuberculosis[J]. BMJ Case Rep, 2016,
10.1136/bcr-2015-213585
. DOI:.
[13]
Sadaphal P , Astemborski J , Graham NM ,et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis[J]. Clin Infect Dis, 2001,33(10):1687-1691. DOI:
10.1086/323896
.
[14]
de Oliveira Uehara SN , Emori CT , Perez RM ,et al. High incidence of tuberculosis in patients treated for hepatitis C chronic infection[J]. Braz J Infect Dis, 2016,20(2):205-209. DOI:
10.1016/j.bjid.2015.12.003
.
[15]
Abutidze A , Bolokadze N , Chkhartishvili N ,et al. Incidence of tuberculosis among HIV/HCV coinfected patients receiving hepatitis C treatment with pegylated interferon and ribavirin in Georgia[J]. Georgian Med News, 2016, (252):10-15.
[16]
Matsuoka S , Fujikawa H , Hasegawa H ,et al. Onset of tuberculosis from a pulmonary latent tuberculosis infection during antiviral triple therapy for chronic hepatitis C[J]. Intern Med, 2016,55(15):2011-2017. DOI:
10.2169/internalmedicine.55.6448
.
[17]
Fukuba R , Kawaratani H , Kubo T ,et al. Tuberculous peritonitis during pegylated interferon plus ribavirin combination therapy in a patient with chronic hepatitis C[J]. Nihon Shokakibyo Gakkai Zasshi, 2014,111(12):2337-2345.
[18]
Teschke R , Danan G . Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue?[J]. Expert Opin Drug Metab Toxicol, 2017,13(4):425-438. DOI:
10.1080/17425255.2017.1252749
.
[19]
Kim WS , Lee SS , Lee CM ,et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury[J]. BMC Infec Dis, 2016,16:50. DOI:
10.1186/s12879-016-1344-2
.
[20]
Lee SS , Lee CM , Kim TH ,et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis[J]. Int J Tuberc Lung Dis, 2016,20(6):800-805. DOI:
10.5588/ijtld.15.0668
.
[21]
Saha A , Shanthi FX , Winston AB ,et al. Prevalence of hepatotoxicity from antituberculosis therapy: a five-year experience from South India[J]. J Prim Care Community Health, 2016,7(3):171-174. DOI:
10.1177/2150131916642431
.
[22]
Chang TE , Huang YS , Chang CH ,et al. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis[J]. J Chin Med Assoc, 2018,81(2):111-118. DOI:
10.1016/j.jcma.2017.10.002
.
[23]
Lomtadze N , Kupreishvili L , Salakaia A ,et al.
Hepatitis C Virus
co-infection increases the risk of antituberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis
[J]. PLoS One, 2013,8(12):e83892. DOI:
10.1371/journal.pone.0083892.eCollection2013
.
[24]
Wang NT , Huang YS , Lin MH ,et al. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis[J]. J Chin Med Assoc, 2016,79(7):368-374. DOI:
10.1016/j.jcma.2015.12.006
.
[25]
Trigo C , do Brasil PE , Costa MJ ,et al. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment[J]. J Viral Hepat, 2016,23(12):1027-1035. DOI:
10.1111/jvh.12583
.
[26]
Hussain T , Kulshreshtha KK , Yadav VS ,et al. Human immunodeficiency virus and hepatitis B virus co-infections among tuberculosis patients attending a Model Rural Health Research Unit in Ghatampur, North India[J]. Indian J Med Microbiol, 2015,33(4):496-502. DOI:
10.4103/0255-0857.167344
.
[27]
安慧茹，吴雪琼. 抗结核药物性肝损害研究进展[J]. 中国抗生素杂志, 2010,35(10):727-733.
[28]
Guaoua S , Ratbi I , EI Bouazzi O ,et al. NAT2 genotypes in Moroccan patients with hepatotoxicity due to antituberculosis drugs[J]. Genet Test Mol Biomarkers, 2016,20(11):680-684. DOI:
10.1089/gtmb.2016.0060
.
[29]
沈婷婷，张琴，张文宏，等. 中国汉族结核病患者N-乙酰基转移酶2基因型与药物性肝损伤以及抗结核疗效的关系[J]. 中华传染病杂志, 2015,33(6):327-330. DOI:
10.3760/cma.j.issn.1000-6680.2015.06.003
.
[30]
[31]
赖荣陶，陈成伟. 抗结核药物所致肝损伤[J]. 中华肝脏病杂志, 2011,19(8):634-636. DOI:
10.3760/cma.j.issn.1007-3418.2011.08.021
.
[32]
Chen LB , Bao DJ , Gu L ,et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment[J]. BMC Infec Dis, 2018,18(1):295. DOI:
10.1186/s12879-018-3192-8
.
[33]
Zhu CH , Zhao MZ , Chen G ,et al.
Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis fla
res in patients with tuberculosis
[J]. J Hua Zhong Univ Sci Technolog Med Sci, 2017,37(1):105-109. DOI:
10.1007/s11596-017-1702-3
.
[34]
方勇，胡海蜊. 慢性乙肝病毒携带的初治肺结核患者抗结核治疗方案的临床研究[J]. 同济大学学报（医学版）, 2014,35(3):91-94. DOI:
10.3969/j.issnl008-0392.2014.03.021
.
[35]
张明媛，雷建平，闫世明，等. 抗结核药物所致肝损伤及肝病患者抗结核药物治疗-大陆地区诊治建议与台湾《结核病诊治指引》相关介绍[J]. 临床肝胆病杂志, 2015,31(11):1776-1781. DOI:
10.3969/j.issn.100l-5256.2015.11.004
.
[36]
李双初，郭玉霞，程芝，等. 同时进行抗结核和抗丙型肝炎治疗一例[J]. 中国防痨杂志, 2017,39(10):1150-1151. DOI:
10.3969/j.issn.1000-6621.2017,10.024
.
[37]
Alpana M , Daga MK , Aggarwal S ,et al. Treatment for tuberculosis in a patient with Dubin-Johnson syndrome[J]. BMJ Case Rep, 2015,
10.1136/bcr-2015-211123
. DOI:.
[38]
Shang P , Xia Y , Liu F ,et al. Prevalence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China[J]. PLoS One, 2011,6:e21836. DOI:
10.1371/journal.pone.0021836
.
[39]
中华医学会结核病学分会，《中华结核和呼吸杂志编辑委员会》. 抗结核药所致药物性肝损伤诊断与处理专家建议[J]. 中华结核和呼吸杂志, 2013,36(10):732-736. DOI:
10.3760/cma.J.issn.1001-0939.2013.10.007
.
[40]
陈耀凯，严晓峰. 肝病合并结核病患者的抗结核药物治疗研究进展[J]. 中华结核和呼吸杂志, 2013,36(10):769-771. DOI:
10.3760/cmaj.issn.1001-0939.2013.10.016
.
[41]
Abbara A , Chitty S , Roe JK ,et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK[J]. BMC Infec Dis, 2017,17(1):231. DOI:
10.1186/s12879-017-2330-z
.
[42]
Hryshchuk LL , Zhang ZR , Zhang JL ,et al. Ratio of microRNA-122/155 in isoniazid-induced acute liver injury in mice[J]. Exp Ther Med, 2016,12(2):889-894. DOI:
10.3892/etm.2016.3375
.
[43]
Hryshchuk L , Okusok O , Boiko T ,et al. Liver function disorders in patients with first diagnosed pulmonary tuberculosis[J]. Georgian Med News, 2017,(271):49-55. PMID: 29099701.
[44]
Rangel MA , Pais IP , Duarte R ,et al. Antituberculosis drug-induced liver injury with autoimmune features: facing diagnostic and treatment challenges[J]. Case Rep Pediatr, 2017,2017:5741896. DOI:
10.1155/2017/5741896
.
[45]
Prieto LM , Santiago B , Del Rosal T ,et al. Linezolid-containing treatment regimens for tuberculosis in children[J]. Pediatr Infect Dis J, 2019,38(3):263-267. DOI:
10.1097/INF.0000000000002093
.
[46]
Mikus M , Drobin K , Gry M ,et al. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury[J]. Liver Int, 2017,37(1):132-140. DOI:
10.1111/liv.13174
.
[47]
Sun Q , Zhang Q , Gu J ,et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study[J]. Pharmacoepidemiol Drug Saf, 2016,25(8):908-917. DOI:
10.1002/pds.3988
.
[48]
Habibzadeh S , Shahi JM , Ghobadi H ,et al.
The first report of two cases of fatal liver injury due to ant
i-tuberculosis drugs in the presence of alpha-1 antitrypsin deficiency
[J]. Int J Mycobacteriol, 2017,6(2):187-190. DOI:
10.4103/ijmy.ijmy_60_17
.
[49]
中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019,42(5):343-356. DOI:
10.3760/cma.j.issn.1001-0939.2019.05.007
.
[50]
Tweed CD , Wills GH , Crook AM ,et al. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study[J]. BMC Med, 2018,16(1):46. DOI:
10.1186/s12916-018-1033-7
.
备注信息
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
慢性肾脏病合并结核病的治疗专家共识（2022版）
中华医学会结核病学分会 中华结核和呼吸杂志 2022,45(10)
"2020世界卫生组织结核病整合指南之预防性治疗"解读
杨松 等 国际呼吸杂志 2021,41(03)
耐药结核病的诊治进展
初乃惠 等 中华传染病杂志 2021,39(07)
特殊人群(慢性肝病、结核病和风湿免疫病患者)新型冠状病毒疫苗接种专家建议
中华医学会感染病学分会 等 中华传染病杂志 2021,39(07)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
